(Q34336342)

English

Enhanced anti-tumor activity of the glycoengineered type II CD20 antibody obinutuzumab (GA101) in combination with chemotherapy in xenograft models of human lymphoma

scientific article

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Enhanced anti-tumor activity of the glycoengineered type II CD20 antibody obinutuzumab (GA101) in combination with chemotherapy in xenograft models of human lymphoma (English)

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Frank Herting

1

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Thomas Friess

2

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Sabine Bader

3

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Gunter Muth

4

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Gabriele Hölzlwimmer

5

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Natascha Rieder

6

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Pablo Umana

7

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Christian Klein

8

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

publication date

4 February 2014

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Leukemia & Lymphoma

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

55

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

9

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

2151-5160

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Anti-CD20 antibody therapy for B-cell lymphomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4196549

6 July 2018

Antibody-induced nonapoptotic cell death in human lymphoma and leukemia cells is mediated through a novel reactive oxygen species-dependent pathway

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4196549

6 July 2018

Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4196549

6 July 2018

Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4196549

6 July 2018

Preclinical studies on the mechanism of action and the anti-lymphoma activity of the novel anti-CD20 antibody GA101.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4196549

6 July 2018

Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4196549

6 July 2018

Rituximab for the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukaemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4196549

6 July 2018

Treatment of follicular lymphoma: current status

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4196549

6 July 2018

Bendamustine--a new approach to the treatment of advanced hepatocellular carcinoma?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4196549

6 July 2018

Antitumor activity of fludarabine against human multiple myeloma in vitro and in vivo

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4196549

6 July 2018

Albumin conjugates of the anticancer drug chlorambucil: synthesis, characterization, and in vitro efficacy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4196549

6 July 2018

A unique cell surface antigen identifying lymphoid malignancies of B cell origin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4196549

6 July 2018

The addition of bryostatin 1 to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy improves response in a CHOP-resistant human diffuse large cell lymphoma xenograft model.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4196549

27 October 2018

Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation

1 reference

https://pubmed.ncbi.nlm.nih.gov/24304419

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of the in vitro effects of the anti-CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/24304419

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.3109/10428194.2013.856008

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34336342&oldid=1954684576"